Literature DB >> 11260065

Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura.

F Fabris1, T Tassan, R Ramon, G Carraro, M L Randi, G Luzzatto, P Moschino, A Girolami.   

Abstract

Sixty-one consecutive patients undergoing splenectomy for chronic immune thrombocytopenia were retrospectively evaluated. Platelet response was considered as complete (CR) when platelet count rose to > 100 x 109/l, partial (PR) when 30-100 x 109/l or absent (NR) if otherwise. Follow-up (mean time 7.6 years) was possible in 54 patients. Forty-eight patients (88%) had an immediate response to splenectomy (39 CR, 9 PR) whereas six (12%) were NR. Thirty-six responders (67%) had sustained remission (31 CR; 5 PR) without further treatment; thrombocytopenia recurred in 12 patients (33%). The probability curve of continued remission showed a constant relapse-rate during the first 36 months; a further step of relapse was observed beginning 70 months after surgery. The only positive predictive factor for the long-term response to splenectomy was age < 40 (P < 0.005). Neither duration of thrombocytopenia nor previous response to medical treatment (steroids and/or intravenous immunoglobulins) were related to splenectomy response.

Entities:  

Mesh:

Year:  2001        PMID: 11260065     DOI: 10.1046/j.1365-2141.2001.02615.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Laparoscopic splenectomy in the elderly: a morbid procedure?

Authors:  S M Kavic; R D Segan; A E Park
Journal:  Surg Endosc       Date:  2005-10-03       Impact factor: 4.584

Review 2.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

3.  Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura: study of clinical and laboratory data.

Authors:  C Balagué; S Vela; E M Targarona; I J Gich; E Muñiz; A D'Ambra; A Pey; V Monllau; E Ascaso; C Martinez; J Garriga; M Trias
Journal:  Surg Endosc       Date:  2006-07-24       Impact factor: 4.584

4.  Prognostic factors of response to laparoscopic splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  Hyuk-Chan Kwon; Chang-Hoon Moon; Young-Rak Cho; Min-Chan Kim; Kyeong-Hee Kim; Jin-Yeong Han; Young-Ho Lee; Sung-Yong Oh; Sung-Hyun Kim; Jae-Seok Kim; Hyo-Jin Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

5.  Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle.

Authors:  Andreas Rank; Oliver Weigert; Helmut Ostermann
Journal:  Biologics       Date:  2010-05-25

6.  Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomy.

Authors:  Jae Joon Han; Sun Kyung Baek; Jae Jin Lee; Si-Young Kim; Kyung Sam Cho; Hwi-Joong Yoon
Journal:  Korean J Hematol       Date:  2010-09-30

7.  Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia.

Authors:  Mingjun Wang; Mengni Zhang; Jin Zhou; Zhong Wu; Ke Zeng; Bing Peng; Ting Niu
Journal:  Int J Hematol       Date:  2013-04-17       Impact factor: 2.490

8.  Can rituximab replace splenectomy in immune thrombocytopenic purpura?

Authors:  Vrushali Dabak; Amr Hanbali; Philip Kuriakose
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

9.  Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  A Shojaiefard; S A Mousavi; S H Faghihi; S Abdollahzade
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

10.  Proteomics-based identification of haptoglobin as a favourable serum biomarker for predicting long-term response to splenectomy in patients with primary immune thrombocytopenia.

Authors:  Chao-Xu Zheng; Zhuang-Qi Ji; Long-Juan Zhang; Qiong Wen; Liu-Hua Chen; Jun-Feng Yu; Dong Zheng
Journal:  J Transl Med       Date:  2012-10-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.